Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 1.00 |
| ▸ | DRD2 | P14416 | 10/20 | 1.00 |
| ▸ | DRD4 | P21917 | 8/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.82 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.82 |
| ▸ | DRD1 | P21728 | 4/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.82 |
| ▸ | HRH1 | P35367 | 4/20 | 0.82 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.82 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.82 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.82 |
| ▸ | HTR1A | P08908 | 3/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.82 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.82 |
| ▸ | HTR2A | P28223 | 3/20 | 0.82 |
| ▸ | HTR2C | P28335 | 3/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoclozapine SCHEMBL29822724 | 1.00 | CHRM1 (1.00) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL29590817 | 0.90 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL29433929 | 0.90 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL29360001 | 0.90 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL20876213 | 0.90 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL8397 | 0.90 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL5501558 | 0.90 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL28700741 | 0.89 | DRD2 (0.98) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL140458 | 0.89 | DRD2 (0.98) | CHRM1DRD2DRD4DRD3CHRM2 | |
| Clozapine SCHEMBL29180214 | 0.89 | DRD2 (0.98) | CHRM1DRD2DRD4DRD3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561234-B2 | Methods for treating diseases of the retina | ALLERGAN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561234-B2 | Methods for treating diseases of the retina | ALLERGAN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150290215-A1 | METHODS FOR TREATING DISEASES OF THE RETINA | ALLERGAN, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150290215-A1 | METHODS FOR TREATING DISEASES OF THE RETINA | ALLERGAN, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9018202-B2 | Methods for treating diseases of the retina | ALLERGAN, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018202-B2 | Methods for treating diseases of the retina | ALLERGAN, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2646034-A1 | METHODS FOR TREATING DISEASES OF THE RETINA | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2013070107-A1 | 5H-DIBENZO[B,E][1,4]DIAZEPINE DERIVATIVES AND USE THEREOF | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТЕК" (RU) | 2013-05-16 | — | — | WO | disclosed |
| US-20120142675-A1 | Methods for Treating Diseases of the Retina | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142675-A1 | Methods for Treating Diseases of the Retina | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| US-20040184997-A1 | Delivery of antipsychotics through an inhalation route | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-09-23 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040156791-A1 | Delivery of antipsychotics through an inhalation route | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-6716416-B2 | AN AEROSOL FOR INHALATION THERAPY, WHEREIN THE AEROSOL COMPRISES PARTICLES COMPRISING AT LEAST 10 PERCENT BY WEIGHT OF AN ANTIPSYCHOTIC SUCH AS OLANZAPINE, TRIFLUOPERAZINE, HALOPERIDOL, LOXAPINE, CLOZAPINE, QUETIAPINE, PROMAZINE, ETC. | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20030017118-A1 | Delivery of antipsychotics through an inhalation route | ALEXZA PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290215-A1 | METHODS FOR TREATING DISEASES OF THE RETINA | ALDH1A2, NR2E3, NLN | CHRM1 451/4885DRD2 81/4885DRD4 78/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | CHRM1 3915/4885DRD2 3053/4885DRD4 2515/4885 |
| US-20120142675-A1 | Methods for Treating Diseases of the Retina | ALDH1A2, NR2E3, NLN | CHRM1 451/4885DRD2 81/4885DRD4 78/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | CHRM1 4670/4885DRD2 4506/4885DRD4 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.